United Therapeutics (UTHR) Receivables (2009 - 2026)

United Therapeutics has disclosed Receivables across 18 years of filings, most recently posting $312.0 million for Q1 2026.

• Receivables for Q1 2026 came in at $312.0 million, down 3.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $312.0 million (down 3.11% YoY), and the FY2025 annual result was $350.2 million, up 25.38% from the prior year.
• Receivables came in at $312.0 million for Q1 2026 at United Therapeutics, down from $350.2 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $379.3 million in Q2 2025 to a low of $134.5 million in Q1 2023.
• The 5-year median for Receivables is $279.3 million (2024), against an average of $271.8 million.
• Across the five-year window, Receivables fell 21.11% in 2023 and soared 128.48% in 2024, its largest moves.
• United Therapeutics' Receivables stood at $220.4 million in 2022, then gained by 26.54% to $278.9 million in 2023, then advanced by 0.14% to $279.3 million in 2024, then rose by 25.38% to $350.2 million in 2025, then retreated by 10.91% to $312.0 million in 2026.
• The last three Receivables figures came in at $312.0 million (Q1 2026), $350.2 million (Q4 2025), and $297.7 million (Q3 2025), per Business Quant data.